NETest can predict the tumour burden in neuroendocrine tumours

#4410

Introduction: Neuroendocrine tumours (NETs) are rare malignancies characterised by slow growth and a lack of reliable biomarkers for predicting tumour burden, treatment response, and prognosis.

Aim(s): This study investigated the efficacy of NETest, a blood-based biomarker test, in assessing the tumour burden, and progression rate in NETs.

Materials and methods: In this prospective study, 3 ml peripheral blood was analysed via quantitative PCR to determine NETest scores. The NETest include the NScore (molecular histology) and PScore (cellular proliferation activity), which are combined into the TScore. Patients were stratified into two groups via imaging modalities, including tumour-present and non-tumour group.

Conference:

Presenting Author:

Authors: You T, Zhou N, Tang H, Ying J, Wang C,

Keywords: NETest, biomarker, NET,